As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria

Ataru Igarashi, Associate Professor, University of Tokyo Graduate School of Pharmaceutical Sciences With the FDA’s verdict on aducanumab imminent, a University of Tokyo health economist says the value of the first disease-modifying therapy that might be approved should be assessed...read more